GlobeNewsWire
26 Jun 2026, 21:15 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Matinas BioPharma received a notice from the NYSE American stating it is not in compliance with continued listing standards due to insufficient stockholders' equity. — Failure to meet exchange listing requirements signals financial distress and creates the risk of delisting, which typically reduces liquidity and investor confidence.
-0.60As of March 31, 2026, the company had stockholders' equity of $3.02 million and has reported losses in the five most recent fiscal years. — Confirmed persistent losses and low equity highlight a precarious financial position and a likely need for dilutive financing.
-0.40The NYSE American has accepted the company's compliance plan, granting a plan period until October 2, 2027, to regain compliance. — This provides a significant runway for the company to raise capital or improve its balance sheet without facing immediate delisting.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company received a notice of non-compliance with NYSE American listing standards due to insufficient stockholders' equity and persistent losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
3h ago
